Highlights of the 29th Congress of the European Committee for Treatment and Research in MS (ECTRIMS), Copenhagen, DK, October 2-5, 2013 – Two new analyses have examined the relative merits of maintaining treatment with a first-line injectable compared to escalating therapy. A US study retrospectively analysed a claims database to identify MS patients managed with a lateral switch from an interferon to glatiramer acetate, and those managed with treatment escalation from an interferon to fingolimod during a one-year period (October 2010 to September 2011) (Bergvall et al. ECTRIMS 2013; abstract P635).